Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 99

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9B
Chunk 99
---
 the financial statements. Our audit also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provided
a reasonable basis for our opinion.

/s/
Cherry Bekaert LLP

We
served as the Company’s auditor from 2023 to 2024.

Tampa,
Florida

March
29, 2024

F-2

Telomir
Pharmaceuticals, Inc.

BALANCE
SHEETS

    December
    31,  
    December
    31, 

    2024  
    2023 
  
    ASSETS 

    Current assets: 

    Cash 
    $1,266,131  
    $1,231 
  
    Deferred offering costs 
     -  
     303,281 
  
    Prepaid expenses 
     57,874  
     713 
  
    Due
    from related parties 
     -  
     130,000 
  
    Total current assets 
     1,324,005  
     435,225 

    Deferred financing costs 
     -  
     4,338,543 

    Total
    assets 
    $1,324,005  
    $4,773,768 

    LIABILITIES AND STOCKHOLDERS’
    EQUITY 

    Current liabilities: 

    Trade accounts payable
    and accrued liabilities 
    $587,536  
    $707,187 
  
    Due to related parties 
     93,432  
     527,377 
  
    Related
    party line of credit 
     -  
     101,000 
  
    Total current liabilities 
     680,968  
     1,335,564 

    Total liabilities 
     680,968  
     1,335,564 

    Stockholders’ Equity 

    Preferred Stock, no par
    value, 100,000,000 shares authorized and none issued or outstanding. 
     -  
     - 
  
    Common Stock, no par value;
    300,000,000 shares authorized, 29,762,671 and 28,609,814 shares issued and outstanding at December 31, 2024 and December 31, 2023,